BDR Pharma launches generic APALUTAMIDE to treat Prostate cancer in India

As per clinical data during SPARTAN trial for patients in Non-metastatic castration resistant Prostate cancer, Apalutamide in combination with anti-androgen therapy significantly improved Median Metastatis – free survival by 02 years. The median progression-free survival for Apalutamide plus ADT arm was 40.5 months v/s 14.7 months for the Placebo arm plus ADT, representing a significant decrease in the risk of disease progression or death by 71%. Also, patients reported outcome indicate maintained overall health-related quality of life with the addition of Apalutamide to androgen-deprivation therapy.

Mr. Raheel Shah, Director Business Development, BDR Group stated that “Early identification of newer molecules for life-threatening diseases encourages us to advance the development & introduction of products through the strength of backward integration of developing & manufacturing APIs to facilitate humankind. This type of advanced molecule in the treatment of various cancer indications, is testimony towards our commitment in providing access to affordable medicines without compromising patients’ safety as well as qualitative standards. At BDR, our goal is to support the vision of the Honourable Prime Minister on being Atmanirbhar Bharat and make affordable and quality medicines accessible for the people of India.”

Read also: BDR Pharma launches Enzalutamide under the brand name BDENZA